HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Leo I Gordon Selected Research

motexafin gadolinium

4/2010Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines.
10/2009The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.
7/2005Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies.
2/2005Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Leo I Gordon Research Topics

Disease

54Neoplasms (Cancer)
01/2022 - 05/2002
45Lymphoma (Lymphomas)
01/2022 - 04/2003
41Non-Hodgkin Lymphoma (Lymphosarcoma)
11/2020 - 02/2002
18Hodgkin Disease (Hodgkin's Disease)
01/2022 - 06/2007
14Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
11/2020 - 06/2004
13B-Cell Lymphoma (Lymphoma, B Cell)
01/2022 - 07/2003
13Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
11/2020 - 02/2008
13Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2018 - 06/2002
7B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2020 - 07/2003
7Hematologic Neoplasms (Hematological Malignancy)
01/2020 - 07/2005
5Lymphoproliferative Disorders (Lymphoproliferative Disorder)
12/2021 - 07/2008
5Multiple Myeloma
05/2018 - 02/2002
4Genetic Translocation (Chromosomal Translocation)
01/2017 - 09/2013
3Burkitt Lymphoma (Burkitt's Lymphoma)
11/2020 - 07/2012
3Thrombocytopenia (Thrombopenia)
10/2013 - 06/2002
2Disease Progression
05/2022 - 01/2020
2COVID-19
04/2022 - 11/2020
2Cytokine Release Syndrome
01/2021 - 05/2018
2Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 01/2015
2Starvation
02/2013 - 07/2003
2Hypoxia (Hypoxemia)
01/2013 - 05/2008
2Leukemia
01/2013 - 09/2012
2Acute Promyelocytic Leukemia
09/2012 - 02/2002
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2007 - 04/2003
2Febrile Neutropenia
06/2007 - 07/2005
1Critical Illness (Critically Ill)
04/2022

Drug/Important Bio-Agent (IBA)

25Rituximab (Mabthera)FDA Link
10/2016 - 05/2002
20ibritumomab tiuxetan (Zevalin)FDA Link
10/2009 - 02/2002
12Proteins (Proteins, Gene)FDA Link
11/2021 - 07/2003
9YttriumIBA
09/2007 - 02/2002
6Pharmaceutical PreparationsIBA
01/2022 - 04/2003
6Dacarbazine (DIC)FDA LinkGeneric
01/2022 - 02/2013
6Monoclonal AntibodiesIBA
11/2021 - 07/2005
6CholesterolIBA
01/2021 - 02/2013
6HDL LipoproteinsIBA
01/2021 - 02/2013
6Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 06/2012
5Vinblastine (Vinblastine Sulfate)FDA Link
01/2019 - 02/2013
5Bleomycin (Blenoxane)FDA LinkGeneric
01/2019 - 06/2007
5Cyclin D1IBA
01/2017 - 08/2011
5Biological ProductsIBA
01/2017 - 05/2002
5Prednisone (Sone)FDA LinkGeneric
10/2016 - 04/2009
5Vincristine (Oncovin)FDA LinkGeneric
10/2016 - 04/2009
5Bortezomib (Velcade)FDA Link
08/2014 - 05/2009
4Chimeric Antigen ReceptorsIBA
05/2022 - 05/2018
4Arsenic Trioxide (Trisenox)FDA Link
01/2013 - 02/2002
4motexafin gadoliniumIBA
04/2010 - 02/2005
4Yttrium-90IBA
04/2009 - 04/2003
3GoldIBA
01/2022 - 02/2013
3Phosphotransferases (Kinase)IBA
11/2021 - 09/2012
3high density lipoprotein receptorsIBA
01/2021 - 02/2013
3Brentuximab VedotinIBA
01/2019 - 05/2014
3Scavenger Receptors (Scavenger Receptor)IBA
01/2019 - 02/2013
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2016 - 04/2009
3Histone Deacetylase InhibitorsIBA
03/2016 - 05/2009
3abexinostatIBA
03/2016 - 05/2009
3Biomarkers (Surrogate Marker)IBA
01/2016 - 06/2006
3DNA (Deoxyribonucleic Acid)IBA
05/2013 - 12/2012
3CaspasesIBA
10/2010 - 05/2009
3PorphyrinsIBA
10/2009 - 02/2005
3Reactive Oxygen Species (Oxygen Radicals)IBA
05/2009 - 02/2005
2Immune Checkpoint InhibitorsIBA
01/2022 - 11/2016
2Immunoconjugates (Immunoconjugate)IBA
11/2021 - 08/2012
2Lipoproteins (Lipoprotein)IBA
01/2021 - 11/2017
2ibrutinibIBA
11/2020 - 01/2017
2Glucocorticoid Receptors (Glucocorticoid Receptor)IBA
01/2020 - 01/2013
2GlucocorticoidsIBA
01/2020 - 01/2013
2Dexamethasone (Maxidex)FDA LinkGeneric
01/2020 - 01/2013
2venetoclaxIBA
04/2018 - 12/2017
2idelalisibIBA
04/2018 - 12/2017
2Bevacizumab (Avastin)FDA Link
12/2015 - 06/2006
2Etoposide (VP 16)FDA LinkGeneric
06/2015 - 04/2013
2Mechlorethamine (Nitrogen Mustard)FDA Link
06/2015 - 04/2013
2Nucleic AcidsIBA
01/2015 - 05/2013
2pidilizumabIBA
09/2014 - 11/2013
2ParaffinIBA
02/2013 - 10/2012
2Formaldehyde (Formol)FDA Link
02/2013 - 10/2012
2CurcuminIBA
08/2011 - 04/2011
2Glutathione (Reduced Glutathione)IBA
08/2010 - 07/2005
1Hemoglobins (Hemoglobin)IBA
04/2022
1axicabtagene ciloleucelIBA
01/2022
1AnthracyclinesIBA
01/2022
1cytidylyl-3'-5'-guanosineIBA
01/2022
1pembrolizumabIBA
11/2021
1Immunoglobulin G (IgG)IBA
11/2021
1IronIBA
01/2021

Therapy/Procedure

51Therapeutics
05/2022 - 06/2002
23Drug Therapy (Chemotherapy)
05/2022 - 06/2002
16Radioimmunotherapy
01/2018 - 02/2002
7Stem Cell Transplantation
01/2022 - 10/2013
4Radiotherapy
01/2022 - 02/2013
4Aftercare (After-Treatment)
05/2009 - 04/2003
3Immunotherapy
12/2021 - 05/2002
2Transplantation
01/2022 - 11/2010
2Precision Medicine
01/2019 - 01/2013
2Lymphatic Irradiation
01/2019 - 06/2014
2Treatment Delay
01/2018 - 10/2013
2Induction Chemotherapy
10/2016 - 07/2010
2Combination Drug Therapy (Combination Chemotherapy)
06/2015 - 11/2013
2Hematopoietic Stem Cell Transplantation
11/2013 - 04/2010
1Photothermal Therapy
01/2022